Summit Therapeutics, Inc., shared on LinkedIn:
“Ivonescimab Monotherapy Demonstrates Statistically Significant Overall Survival Benefit Compared to Pembrolizumab Monotherapy in PD-L1-Positive Advanced NSCLC in HARMONi-2 Study Conducted by Akeso in China.
Summit is Conducting HARMONi-7 in Patients with PD-L1 High-Expressing NSCLC.
Ivonescimab is an investigational therapy not presently approved by any regulatory authority other than China’s National Medical Products Administration (NMPA).”
Other articles about NSCLC on OncoDaily.